18:57:17 EDT Sun 07 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Avicanna Inc
Symbol AVCN
Shares Issued 57,623,781
Close 2022-06-08 C$ 0.275
Recent Sedar Documents

Avicanna completes 1st cannabis seed export to Lesotho

2022-06-09 14:05 ET - News Release

An anonymous director reports

AVICANNA'S SUBSIDIARY SANTA MARTA GOLDEN HEMP COMPLETES FIRST COMMERCIAL EXPORT OF FEMINIZED CANNABIS SEEDS TO LESOTHO

Avicanna Inc., through its majority-owned Colombian subsidiary, Santa Marta Golden Hemp SAS (SMGH), has completed its first commercial export of feminized cannabis seeds to the African region with an initial export to Lesotho.

The development, standardization and production of these seeds were all completed through Avicanna's vertical integration at SMGH located in Santa Marta, Colombia. The standardized and feminized seeds are a part of the Aureus(TM) product portfolio which includes CBD, CBG and THC seeds, resins or whole plant crude oils, cannabinoid distillates, and isolated cannabinoids.

Lucas Nosiglia, President of Avicanna LATAM, commented: "We are happy to see the demand for our proprietary genetics grow internationally. The culmination of our seed development and standardization efforts provides our international partners with the opportunity to cultivate federally registered, reliable and consistent cultivars across various environments and landscapes.

To its knowledge, the Company carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Aureus(TM)

Avicanna's supply chain business unit is based in Santa Marta, Colombia and provides a consistent source of cannabinoid raw materials for the global marketplace. These include active pharmaceutical ingredients and feminized seeds, for Avicanna's cosmetic, medical, and pharmaceutical products, in addition to supplying the company's partners around the world.

Aureus-branded products are cultivated, extracted, and manufactured by Avicanna's subsidiaries in Colombia where they leverage optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically and sustainably with USDA organic and GACP certifications.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto(TM) brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol ("CBD") and tetrahydrocannabinol ("THC"). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox(TM)) is in the drug registration stage in South America.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.